NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas
Clinical Scorecard: NOTCH3 Enhances Fatty Acid Oxidation and Confers Resistance to Ferroptosis in Aggressive Meningioma Tumors
At a Glance
Category Detail
Condition Aggressive meningioma tumors Key Mechanisms NOTCH3 activation promotes fatty acid oxidation (FAO) and protects tumor cells from ferroptosis by depleting fatty acids Target Population Patients with meningiomas expressing NOTCH3, particularly WHO Grade 2 tumors Care Setting Neuro-oncology and surgical oncology settings involving meningioma diagnosis and treatment
Key Highlights
NOTCH3 is a transmembrane receptor involved in cell fate and is overexpressed in aggressive meningiomas. NOTCH3 activation alters tumor lipid metabolism by enhancing fatty acid oxidation, reducing fatty acid availability. This metabolic shift confers resistance to ferroptosis, potentially promoting tumor malignancy and therapeutic resistance. Guideline-Based Recommendations
Diagnosis
Assess NOTCH3 expression in meningioma tissue samples using RT-qPCR or immunoblotting techniques. Use metabolomic and lipidomic profiling to evaluate fatty acid metabolism alterations in tumor cells. Management
Consider targeting NOTCH3 signaling pathways as a potential therapeutic strategy for aggressive meningiomas. Explore interventions that modulate fatty acid oxidation or ferroptosis susceptibility in NOTCH3-expressing tumors. Monitoring & Follow-up
Monitor NOTCH3 expression levels and metabolic markers related to fatty acid oxidation during treatment. Evaluate tumor response and progression with attention to metabolic adaptations conferring ferroptosis resistance. Risks
NOTCH3 overexpression may contribute to tumor growth, angiogenesis, and resistance to radiation therapy. Metabolic adaptations driven by NOTCH3 may lead to poor prognosis due to enhanced tumor survival mechanisms. Patient & Prescribing Data
Patients with WHO Grade 2 meningiomas exhibiting NOTCH3 overexpression
NOTCH3-driven metabolic reprogramming suggests potential benefit from therapies targeting fatty acid oxidation and ferroptosis pathways
Clinical Best Practices
Validate NOTCH3 expression in meningioma samples prior to therapeutic decision-making. Incorporate metabolic profiling to understand tumor biology and resistance mechanisms. Use combined molecular and metabolic data to guide personalized treatment approaches targeting NOTCH3 and associated pathways. References
